Magnesium deficiency and PMDD: Addressing the Root
A week before her period. The woman who moved through a brutal work week with grace is now crying in her car over a text message. She knows this pattern. She has known it for years. Her labs come back normal, and she leaves the visit wondering whether the problem is her.
PMDD is not a hormone disorder in the conventional sense. The estrogen and progesterone levels in women with PMDD are, by and large, normal. What shifts is the brain's response to the luteal-phase rise and fall of allopregnanolone, a metabolite of progesterone, that reliably destabilizes neurological tone in a subset of women. Normal levels. An altered response. This shift can be influenced by low magnesium stores.
What Happens in PMDD
After ovulation, the corpus luteum (the small gland left behind when an egg is released) makes progesterone. Some of that progesterone becomes allopregnanolone, a neurosteroid that acts directly on the brain's GABA-A receptors. GABA is the brain's main calming messenger, and allopregnanolone strengthens its effect. For most women, the rise after ovulation feels like a quieter mind and deeper sleep.
In women with PMDD, the same rise can bring irritability, anxiety and despair. Peter Schmidt and David Rubinow at the National Institute of Mental Health showed this in 1998. They temporarily switched off the ovaries in women with severe premenstrual symptoms, and the symptoms went away. When estradiol or progesterone was added back, symptoms returned only in women with a history of premenstrual mood symptoms. Identical hormones, two different brains.
Lotta Andréen and Torbjörn Bäckström in Sweden found that negative mood in reactive women peaks when allopregnanolone sits in the range a normal luteal phase produces. Then in 2016, Pedro Martinez and colleagues blocked the conversion of progesterone to allopregnanolone with high-dose dutasteride. Irritability, sadness, anxiety, food cravings and bloating all improved compared with placebo. The trigger is a sensitive brain meeting a normal signal.
The therapeutic target in PMDD is supporting the neurological buffering capacity that determines how the brain processes the hormones shifts daily life brings.
Where magnesium fits
A calm brain depends on balance. GABA slows nerve cells down, and glutamate, the brain's main excitatory messenger, speeds them up. Magnesium sits inside the channel of the NMDA receptor, one of glutamate's main receptors, and holds it closed at rest. Most of the ATP in a cell, the molecule cells run on, is bound to magnesium, so the energy-hungry work of clearing and recycling glutamate depends on it too. In rats, a magnesium-deficient diet also makes mast cells release histamine, which may matter for women whose luteal weeks bring flushing, cramping or a reactive gut.
Taken together, low magnesium leaves less buffer on the excitatory side at the moment the calming side becomes unreliable. Magnesium leaves the hormones alone and works on the margin the brain has to absorb them.
Measuring that margin is harder than it sounds. Serum magnesium stays normal until deficiency is severe, because the body pulls from bone and tissue to protect the blood level. A 2019 review of 13 observational studies found no consistent difference in serum or red cell magnesium between women with and without PMS. I weigh diet, stress, alcohol and medications that lower magnesium, such as proton pump inhibitors and some diuretics, alongside any lab result.
What the Trials Show
Likely in part because Magnesium cannot be patented, not enough effort has gone into studying it. This means the randomized controlled trial evidence base is small. That being said, the trials are directionally consistent, every study below enrolled women with PMS or milder premenstrual symptoms, since PMDD was not yet a defined diagnosis when most were run.
Fabio Facchinetti and colleagues (1991) randomized 32 women to magnesium pidolate or placebo from cycle day 15 until the period started. By the second month, magnesium improved total premenstrual scores and the negative mood cluster.
Ann Walker and colleagues (1998) gave 38 women 200 mg of magnesium daily as magnesium oxide. The first cycle showed no effect. In the second, weight gain, swelling, breast tenderness and bloating improved. A woman who stops after one cycle may quit just before the response arrives.
Marilyn De Souza and colleagues (2000) gave 44 women one cycle each of magnesium 200 mg, vitamin B6 50 mg, both together and placebo. Overall the treatments did not differ, but a planned comparison found the combination reduced anxiety-related symptoms. The authors called the effect small.
In 2024, a systematic review in Nutrition Reviews judged the evidence for magnesium on its own insufficient for the psychological symptoms of PMS.
So how do I weigh this? The trials are small, short and done in PMS. Their findings point in one direction, they match the physiology and magnesium carries little risk with healthy kidneys. I use it as one part of a larger plan, and I tell women plainly that the support comes from mechanism and early trials. Ask your lawmakers to support funding for women’s health research.
All magnesium supplements are not created equally.
The most common reason magnesium "doesn't work" for a patient is form. Most inexpensive supplements use magnesium oxide, which has roughly 4% bioavailability and functions primarily as a laxative. Women taking oxide-based products are largely not therapeutically supplementing.
Magnesium cannot exist in a supplement on its own. It is always bound to a carrier — an amino acid, an organic acid, or a salt — and that carrier determines almost everything clinically relevant about the product. It determines how much magnesium actually crosses the intestinal wall and enters circulation. It determines which tissues the magnesium preferentially reaches. And in some cases, the carrier molecule has its own biological activity that compounds or redirects the effect.
Oxide is bound to oxygen. It is poorly soluble, poorly absorbed and pulls water into the gut through osmosis. The result is a bowel movement, not a therapeutic dose. Chelated forms — those bound to amino acids like glycine or organic acids like malic acid — use the body's existing amino acid transporters to move across the intestinal wall. Absorption rates are substantially higher and the magnesium actually reaches the tissues where it is needed. The specific carrier then shapes where it goes from there.
Making your magnesium supplement count*
Dose: Many recommend 300 to 400 mg elemental magnesium per day. The elemental content is what matters for dosing, not the compound weight. A label reading "magnesium glycinate 500 mg" typically delivers approximately 50 mg elemental magnesium. Verify on the supplement facts panel.
Timing: Luteal-phase-only dosing (day 15 through menses) produced benefit in Facchinetti's trial. Continuous dosing is the stronger choice for women with high baseline stress, dietary insufficiency or symptoms that extend beyond the obvious symptomatic window.
B6 co-factor: Pyridoxal-5-phosphate, the active form rather than pyridoxine, at 25 to 50 mg. It supports intracellular magnesium uptake and serotonin synthesis. The De Souza combination outperformed monotherapy.
Timeline: Expect a two-to-three-cycle build toward full response. The most common reason an effective protocol fails is stopping too soon.
Magnesium is not a complete PMDD plan for moderate-severe presentations. It addresses specific physiology within a larger picture that includes chronic inflammation, stress-response calibration, gut function and the lifestyle inputs that set the physiological floor. The clinical question is always what is driving the severity of your particular presentation. But within a full assessment, magnesium addresses real mechanisms that the standard approach often leaves entirely untouched.
If you are tracking your cycle and noticing a consistent luteal-phase pattern, you are on the way to determining you own why. Which symptoms, which days, which triggers, how they respond to sleep, food and stress all add valuable context. Bring that to a clinical conversation. It shapes whether magnesium is the right starting point and how to build the rest of the protocol around it.
Read the label for elemental magnesium, the actual magnesium in each dose. Magnesium glycinate is about 14% elemental, so 500 mg of the compound delivers roughly 70 mg.
Track the pattern
A PMDD diagnosis rests on daily symptom ratings across at least two cycles, and a tool like the Daily Record of Severity of Problems makes that simple. Note which symptoms show up, which days they arrive and leave and how they respond to sleep, food and stress. That record tells your clinician more than a single lab value can.
If your luteal weeks feel unsafe
PMDD can bring thoughts of self-harm. If that happens to you, it is urgent and it is treatable. Call or text 988 any time to reach the Suicide and Crisis Lifeline.
*Not medical advice. Consult with your clinician before starting any new supplements or medications.
About the author
Kailia Wray, CNM, APRN, MN, is a certified nurse-midwife with twenty years in reproductive and hormonal health and a post-graduate focus on metabolic and hormonal care. She founded Recalibrate Women's Wellness, offering telehealth across Oregon and Washington and in-person care in Metro Portland. Read more about Kailia.
References
Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209-216.
Andréen L, Nyberg S, Turkmen S, et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology. 2009;34(8):1121-1132. DOI
Martinez PE, Rubinow DR, Nieman LK, et al. 5α-Reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology. 2016;41(4):1093-1102. PMC
Bois P. Effect of magnesium deficiency on mast cells and urinary histamine in rats. Br J Exp Pathol. 1963;44(2):151-155. PMC
Moslehi M, Arab A, Shadnoush M, Hajianfar H. The association between serum magnesium and premenstrual syndrome: a systematic review and meta-analysis of observational studies. Biol Trace Elem Res. 2019;192(2):145-152. DOI
Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol. 1991;78(2):177-181. PubMed
Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998;7(9):1157-1165. DOI
De Souza MC, Walker AF, Robinson PA, Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms. J Womens Health Gend Based Med. 2000;9(2):131-139. PubMed
Robinson J, Ferreira A, Iacovou M, Kellow NJ. Effect of nutritional interventions on the psychological symptoms of premenstrual syndrome in women of reproductive age: a systematic review of randomized controlled trials. Nutr Rev. 2024.
Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010;65(2):165-177.
NIH Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals.
EFSA Panel on Nutrition, Novel Foods and Food Allergens. Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA J. 2023;21(5):8006. DOI
Management of premenstrual disorders: ACOG Clinical Practice Guideline No. 7. Obstet Gynecol. 2023;142(6):1516-1533.